• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Doing the Right Thing?

Were Walgreen, Time Warner and Allergan too quick to dismiss the fast money?
By JIM CRAMER
Aug 07, 2014 | 11:47 AM EDT
Stocks quotes in this article: WAG, TWX, FOX, FOXA, AGN, VRX, TIME

Did Walgreen (WAG) do the right thing in not cutting its tax bill? Would it have been better just to take advantage of the law, a law that really and truly did support the notion that Walgreen could become a real foreign company after it closes its deal to swallow drugstore giant Alliance Boots?

Did Time Warner (TWX) do the right thing deciding not to engage with Twenty-First Century Fox (FOX/FOXA) on its now withdrawn $85 a share bid?

Is Allergan (AGN) spurning its shareholders' wishes by fighting off the $180 hostile bid from Valeant Pharmaceuticals (VRX)?

All three of these stories right now could be marking what some might regard as the high water mark of this current wave of mergers, acquisitions and inversions -- a wave that has caused a huge spur to the market and one it continues to need quite badly, especially in light of the new Russian headwinds.

All three of these stories involve strong CEOs who have worked hard to create value. David Pyott, the CEO of Allergan, has worked mightily to create a research and development powerhouse, actually reaping profits from his industry-high science spending and growing faster than any other major old-line pharmaceutical.

Time Warner CEO Jeff Bewkes has done a remarkable job of creating amazing value out of an empire that was eviscerated by his predecessors. The company's true worth was just beginning to shine through when he spun off Time Inc. (TIME), the once front-and-center but now vestigial print arm of the company.

Greg Wasson has taken Walgreen from a sleepy regional to a national story to a worldwide dynamo, with the Alliance Boots deal giving it unprecedented power in the tug-of-war against the drug companies. It will be the biggest buyer of medicines in the world, which means the best discounts for its customers.

I think Wasson will do whatever is right for shareholders and while some of the more aggressive short-term-oriented hedge funds wanted Wasson to invert Walgreen, I think Wasson was genuinely concerned that his company would become the poster child for negative financial engineering. It is true that he has a much better case than the other companies that have inverted, as the targets largely used Europe as a mail drop while Alliance Boots had $29 billion in sales overseas last year, but I don't think that the possibility of as much as 40% of the combined sales of the company coming from overseas would shield this company from the wrath of a President who, like Walgreen, is from Chicago. It's just too visible. I think Wasson did the right thing.

Bewkes? I don't know. I think that the shareholders were entitled to a discussion with Fox to see how high Murdoch would go. I believe in Bewkes and his ability to create value long-term, if only because he has beaten the S&P three times over since his tenure began, but if Murdoch had been willing to pay $95, which is more than a third more than the stock was trading at before the bid, I think that merited a thorough analysis instead of a dismissal.

Allergan? I think that before Pyott revealed his more aggressive forecasts, it did seem that, no matter how reprehensible someone might find the twin predators of Bill Ackman and the research-light Valeant, it made sense to sell. Once we saw the bigger numbers, though, I am confident that Pyott will steer Allergan north of where the duo could take it. Still, though, thoughtful engagement was merited, and Allergan hasn't chosen that route.

In the end, it comes down to short-term versus long-term. Put simply, it doesn't matter what Bewkes, Pyott or Wasson ultimately did. The stocks ran up big on the inversion and bid stories. You have to exercise some responsibility yourself, as no one kept you from taking profits. You accepted the nuisance that the CEOs would reject these entreaties. Shame on you, not shame on them, if you didn't take them.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publcation, Action Alerts PLUS, which Cramer co-manages as a charitable trust, had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare | Consumer Discretionary

More from Healthcare

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

It's an Opportune Time to Renew Your Vows With CVS Health

Paul Price
Feb 18, 2021 7:00 AM EST

The pharmacy giant offered a great buy/write options play last summer and is setting up again for such action.

Just Had My First Teladoc Appointment: Is the Rally Over?

Bruce Kamich
Feb 17, 2021 2:39 PM EST

I may be late to trends, but not to stock charts.

CVS Health Reports Q4, and Here's What I'm Changing Up

Stephen Guilfoyle
Feb 16, 2021 10:55 AM EST

I do want to give new CEO Karen Lynch a chance. Nothing against Larry Merlo but I always thought that this stock was undervalued.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login